Amarin to Present at the 40th Annual J.P. Morgan Healthcare Conference
Amarin Corporation (NASDAQ: AMRN) announced that CEO Karim Mikhail will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 8:15 AM ET. The presentation will be available via a live webcast on the company's investor relations website, where it will also be archived for 30 days. Amarin is dedicated to transforming cardiovascular disease management through innovative research and clinical trials, with a commitment to advancing treatments beyond traditional therapies.
- None.
- None.
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today announced that Karim Mikhail, president and chief executive officer of Amarin, is scheduled to present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 8:15 am ET.
A live webcast of the presentation will be accessible under Events in the Investor Relations section of the company’s website at https://investor.amarincorp.com/events-and-presentations/events. The webcast will be archived for 30 days.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our foundation in scientific research to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk.
Availability of Other Information About Amarin
Amarin communicates with its investors and the public using the company website (www.amarincorp.com) and the investor relations website (investor.amarincorp.com), including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor Inquiries:
Investor Relations
Amarin Corporation plc
In U.S.: +1 (908) 719-1315
IR@amarincorp.com (investor inquiries)
Solebury Trout
In U.S.: +1 (646) 378-2992
amarinir@troutgroup.com
Media Inquiries: Communications
Amarin Corporation plc
In U.S.: +1 (908) 892-2028
PR@amarincorp.com (media inquiries)
FAQ
When is Amarin's presentation at the J.P. Morgan Healthcare Conference?
Who will present for Amarin at the conference?
Where can I watch the Amarin presentation?
What is Amarin's focus in the pharmaceutical industry?
What are Amarin's contact details for investor inquiries?
